Candel therapeutics announces oral presentation of updated data from its phase 1 clinical trial of can-3110 in 41 patients with recurrent high-grade glioma at the society for neuro-oncology 27th annual meeting

Needham, mass., nov. 18, 2022 (globe newswire) -- candel therapeutics, inc. (“candel” or “the company”) (nasdaq: cadl), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of updated data from a phase 1 clinical trial of can-3110 in patients with recurrent high-grade glioma (rhgg). an overview of this data will be presented in-person at the society for neuro-oncology (sno) 27th annual meeting today starting at 5:30 pm et in tampa, florida.
CADL Ratings Summary
CADL Quant Ranking